Ontology highlight
ABSTRACT:
SUBMITTER: Schelter BO
PROVIDER: S-EPMC6918900 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
Schelter Bjoern O BO Shiells Helen H Baddeley Thomas C TC Rubino Christopher M CM Ganesan Harish H Hammel Jeffrey J Vuksanovic Vesna V Staff Roger T RT Murray Alison D AD Bracoud Luc L Riedel Gernot G Gauthier Serge S Jia Jianping J Bentham Peter P Kook Karin K Storey John M D JMD Harrington Charles R CR Wischik Claude M CM
Journal of Alzheimer's disease : JAD 20190101 3
<h4>Background</h4>Although hydromethylthionine is a potent tau aggregation inhibitor, no difference was found in either of two Phase III trials in mild to moderate Alzheimer's disease (AD) comparing doses in the range 150-250 mg/day with 8 mg/day intended as a control.<h4>Objective</h4>To determine how drug exposure is related to treatment response.<h4>Methods</h4>A sensitive plasma assay for the drug was used in a population pharmacokinetic analysis of samples from 1,162 of the 1,686 patients ...[more]